20 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Kurian, Medical Oncologist in Stanford, CA?
Dr. Allison Kurian, MD is a Medical Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. She has been practicing for over 20 years and is board certified by the American Board of Internal Medicine. Dr. Kurian graduated from Harvard Medical School, Boston, Massachusetts and completed her residency at Massachusetts General Hospital. Dr. Kurian is fluent in English, French, and Spanish, and is currently seeing new patients. Dr. Kurian’s practice accepts Kaiser Permanente, Medicaid, Medicare, UnitedHealthcare, Aetna, Cigna and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Kurian’s office at (650) 723-4000.
What are Areas of Expertise for Dr. Kurian?
Dr. Allison Kurian, MD is a highly-rated, board-certified Medical Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions or procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Kurian empowers patients to confidently navigate their health journey, specializing in Breast Cancer Risk Assessment, Cancer Genetics, Gynecologic Cancers, or comprehensive wellness support. Serving the Stanford/CA community, Dr. Kurian is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Kurian go to medical school and complete their residency?
Fellowship: Stanford University School of Medicine CA | Stanford University School of Medicine,Stanford, Ca, United States
Residency: Massachusetts General Hospital
Medical School: Harvard Medical School, Boston, Massachusetts
Is Dr. Kurian board certified in Medical Oncologist?
Yes, Dr. Allison Kurian, MD is board certified by the American Board of Internal Medicine since 2005
What languages does Dr. Kurian speak?
Dr. Kurian and their clinical team can communicate with patients in the following languages:
English
French
Spanish
What conditions does Dr. Kurian treat?
As a Medical Oncologist, Dr. Kurian diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Kurian. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.
Also known as:
- Breast Cancer
- Genetic Susceptibility to Breast Cancer
- Upper-Outer Quadrant Right Female Breast Cancer
- Right Female Nipple and Areola Breast Cancer
- Left Female Nipple and Areola Breast Cancer
- Early Breast Cancer of the Left Breast
- Breast cancer
- Li-Fraumeni syndrome
- Female Breast Cancer
- Malignant Breast Tumor
- Breast Carcinoma
- Mammary cancer
- Breast carcinoma
- Breast tumor
- Inherited Breast Cancer Risk
- Hereditary Breast Cancer
- BRCA Gene Mutation
- Right female breast cancer upper-outer
- Upper-outer right female breast tumor
- Malignant growth in upper-outer right female breast
- Cancer of right female nipple
- Right female areola tumor
- Malignant growth on right female nipple
- Cancer of left female nipple
- Left female areola tumor
- Malignant growth on left female nipple
- Intraductal carcinoma in situ left breast
- Precancerous cells left breast
- Non-invasive breast cancer left breast
- DCIS left breast
ICD-10 Codes:
- C50919: Malignant neoplasm of unspecified site of unspecified female breast
- C50912: Malignant neoplasm of unspecified site of left female breast
- C50911: Malignant neoplasm of unspecified site of right female breast
- C50412: Malignant neoplasm of upper-outer quadrant of left female breast
- Z1501: Genetic susceptibility to malignant neoplasm of breast
- C50411: Malignant neoplasm of upper-outer quadrant of right female breast
- C50011: Malignant neoplasm of nipple and areola, right female breast
- C50012: Malignant neoplasm of nipple and areola, left female breast
- C50811: Malignant neoplasm of overlapping sites of right female breast
- D0512: Intraductal carcinoma in situ of left breast
Also known as:
- Family History of Breast Cancer
- Family History of Ovarian Cancer
- Breast Cancer
- Family History
- Ovarian Cancer
- Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)
- Hereditary breast cancer risk
- Genetic predisposition to breast cancer
- Breast cancer in the family
- Genetic risk for ovarian cancer
- Hereditary ovarian cancer
- Family history of female reproductive cancer
ICD-10 Codes:
- Z803: Family history of malignant neoplasm of breast
- Z8041: Family history of malignant neoplasm of ovary
Also known as:
- Genetic Counseling
- Genetic risk assessment
- Hereditary counseling
- DNA counseling
ICD-10 Codes:
- Z7183: Encounter for nonprocreative genetic counseling
Also known as:
- Genetic Disease Carrier Screening
- Genetic Testing
- Health Screening
- Genetic Carrier Test
- Hereditary Disease Carrier Screening
- Preconception Genetic Screening
ICD-10 Codes:
- Z1371: Encounter for nonprocreative screening for genetic disease carrier status
Also known as:
- Personal History of Breast Cancer
- Breast Cancer
- Past breast cancer
- Previous mammary malignancy
- History of breast tumor
ICD-10 Codes:
- Z853: Personal history of malignant neoplasm of breast
Also known as:
- Breast Cancer Screening
- Health Screening
- Breast Cancer Screening (PDQ®)
- Mammogram
- Breast Exam
- Breast Cancer Check
ICD-10 Codes:
- Z1239: Encounter for other screening for malignant neoplasm of breast
Also known as:
- Secondary Bone Cancer
- Bone Cancer
- Metastatic bone cancer
- Cancer spread to bone
- Bone metastases
ICD-10 Codes:
- C7951: Secondary malignant neoplasm of bone
Also known as:
- Mammogram for Breast Cancer Screening
- Health Screening
- Mammography
- Breast Cancer Screening (PDQ®)
- Mammograms
- Breast X-ray
- Breast Cancer Check
ICD-10 Codes:
- Z1231: Encounter for screening mammogram for malignant neoplasm of breast
Also known as:
- Ovarian Cancer
- Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
- Cancer of the ovary
- Ovarian carcinoma
- Female reproductive cancer
ICD-10 Codes:
- C569: Malignant neoplasm of unspecified ovary
Also known as:
- Family history of genetic disease carrier
- Family History
- Genetic Disorder
- Inherited genetic disease risk
- Genetic carrier status in family
- Family history of inherited conditions
ICD-10 Codes:
- Z8481: Family history of carrier of genetic disease
Which procedures does Dr. Kurian perform as a Medical Oncologist?
As a Medical Oncologist, procedures performed by a Dr. Allison Kurian may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
For detailed information, please contact Dr. Kurian's office.
Does Dr. Kurian accept my insurance?
Dr. Kurian accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Kurian accept in Stanford, CA?
Dr. Kurian in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Central California Alliance for Health
CVS Health (formerly Aetna)
Express Scripts
Medicaid
Medicare
Other Provider Networks
Santa Clara Family Health Plan
UnitedHealthcare
View All Insurances
Where is Dr. Kurian's office located?
Recognitions
Awards
California Breast Cancer Research Program
Translational Research Award
Robert Wood Johnson Foundation
Physician Faculty Scholars Award
American Society of Clinical Oncology
Young Investigator Award
Cancer Research and Prevention Foundation
Fellowship Award
California Breast Cancer Research Program
Fellowship Award
American Society of Clinical Oncology
Merit Award
California Breast Cancer Research Program
Cornelius L. Hopper Research Abstract Award
National Institutes of Health
BIRCWH K12 Scholar Award
Top 12 publications funded by the Epidemiology and Genomics Research
Stanford University Cancer Institute
Suzanne Pride Bryan Award for Breast Cancer Research
Stanford University Cancer Institute
New Clinical Investigator Award
Stanford University Cancer Institute
Jan Weimer Faculty Chair for Breast Oncology
Publications
Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment.
Jourl of clinical oncology : official jourl of the American Society of
Online Tool to Guide Decisions for BRCA1/2 Mutation Carriers
JOURL OF CLINICAL ONCOLOGY, 2012
Oncoshare: lessons learned from building an integrated multi
AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium, 2012
Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations
JOURL OF CLINICAL ONCOLOGY, 2011
Survival Alysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers
JOURL OF CLINICAL ONCOLOGY, 2010
Second Primary Breast Cancer Occurrence According to Hormone Receptor Status
JOURL OF THE TIOL CANCER INSTITUTE, 2009
Performance of BRCA1/2 mutation prediction models in Asian Americans
JOURL OF CLINICAL ONCOLOGY, 2008
A cost-effectiveness alysis of adjuvant trastuzumab regimens in early HER2
JOURL OF CLINICAL ONCOLOGY, 2007
Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonce imaging
JAMA-JOURL OF THE AMERICAN MEDICAL ASSOCIATION, 2006
Obesity and Mortality After Breast Cancer by Race
AMERICAN JOURL OF EPIDEMIOLOGY, 2014
A young woman with bilateral breast cancer
Jourl of the tiol Comprehensive Cancer Network, 2013
Information technology interventions to improve cancer care
JOURL OF ONCOLOGY PRACTICE, 2013
A Population-Based Observatiol Study of First
JOURL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, 2013
Age-Specific Incidence of Breast Cancer Subtypes: Understanding the BlackWhite Crossover
JOURL OF THE TIOL CANCER INSTITUTE, 2012
Single Cell Profiling of Circulating Tumor Cells
PLOS ONE, 2012
Accuracy of BRCA1/2 Mutation Prediction Models
WORLD JOURL OF SURGERY, 2012
In reply to Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations
JOURL OF CLINICAL ONCOLOGY, 2012
A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer
ANLS OF SURGICAL ONCOLOGY, 2011
High-resolution melting alysis for rapid screening of BRCA2 founder mutations in Southern Chinese
BREAST CANCER RESEARCH AND TREATMENT, 2010
Genetic/familial high-risk assessment: breast and ovarian.
Jourl of the tiol Comprehensive Cancer Network, 2010
Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California
JOURL OF CLINICAL ONCOLOGY, 2010
In reply to 'Tailoring BRCRAPRO to Asian Americans?' by S. Chen et al
JOURL OF CLINICAL ONCOLOGY, 2009
The Decline in Breast Cancer Incidence: Real or Imagiry?
CURRENT ONCOLOGY REPORTS, 2009
Magnetic resonce galactography
BREAST JOURL, 2008
CDH1 truncating mutations in the E-cadherin gene
ANLS OF SURGERY, 2007
Ductal pattern enhancement on magnetic resonce imaging of the breast due to ductal lavage
BREAST JOURL, 2007
Breast magnetic resonce image screening
CANCER, 2004
Breast cancer treatment across health care systems
Cancer, 2014
Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment.
Journal of clinical oncology : official journal of the American Societ
Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California
BREAST CANCER RESEARCH AND TREATMENT, 2013
Online Tool to Guide Decisions for BRCA1/2 Mutation Carriers
JOURNAL OF CLINICAL ONCOLOGY, 2012
Oncoshare: lessons learned from building an integrated multi
AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium, 2012
Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations
JOURNAL OF CLINICAL ONCOLOGY, 2011
Survival Analysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers
JOURNAL OF CLINICAL ONCOLOGY, 2010
Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups
BREAST CANCER RESEARCH, 2010
Second Primary Breast Cancer Occurrence According to Hormone Receptor Status
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009
Performance of BRCA1/2 mutation prediction models in Asian Americans
JOURNAL OF CLINICAL ONCOLOGY, 2008
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2
JOURNAL OF CLINICAL ONCOLOGY, 2007
Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006
Histologic types of epithelial ovarian cancer: have they different risk factors?
GYNECOLOGIC ONCOLOGY, 2005
Obesity and Mortality After Breast Cancer by Race
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2014
Response.
Radiology, 2014
The California Breast Cancer Survivorship Consortium (CBCSC)
CANCER CAUSES & CONTROL, 2013
A young woman with bilateral breast cancer
Journal of the National Comprehensive Cancer Network, 2013
Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers
FAMILIAL CANCER, 2013
The California Breast Density Information Group
RADIOLOGY
Information technology interventions to improve cancer care
JOURNAL OF ONCOLOGY PRACTICE, 2013
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
BREAST CANCER RESEARCH AND TREATMENT, 2013
Impact of breast cancer subtypes on three-year survival among adolescent and young adult women
BREAST CANCER RESEARCH, 2013
A Population-Based Observational Study of First
JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, 2013
Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients
BREAST CANCER RESEARCH AND TREATMENT, 2012
Identification of BRCA1
PLOS ONE, 2012
Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations
FAMILIAL CANCER, 2012
A Simulation Model to Predict the Impact of Prophylactic Surgery
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2012
Age-Specific Incidence of Breast Cancer Subtypes: Understanding the BlackWhite Crossover
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012
Single Cell Profiling of Circulating Tumor Cells
PLOS ONE, 2012
Patient, Hospital, and Neighborhood Factors Associated with Treatment of Early
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2012
Accuracy of BRCA1/2 Mutation Prediction Models for Different Ethnicities and Genders: Experience in
WORLD JOURNAL OF SURGERY, 2012
In reply to Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations
JOURNAL OF CLINICAL ONCOLOGY, 2012
Genetic Polymorphisms as Predictors of Breast Cancer Risk
CURRENT BREAST CANCER REPORTS, 2012
Occurrence of breast cancer subtypes in adolescent and young adult women
BREAST CANCER RESEARCH, 2012
A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer
ANNALS OF SURGICAL ONCOLOGY, 2011
Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry
BREAST CANCER RESEARCH AND TREATMENT, 2011
Hereditary cancer: counseling women at risk
CONTEMPORARY OBSTETRICS AND GYNECOLOGY, 2011
High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese
BREAST CANCER RESEARCH AND TREATMENT, 2010
Genetic/familial high-risk assessment: breast and ovarian.
Journal of the National Comprehensive Cancer Network, 2010
Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California
JOURNAL OF CLINICAL ONCOLOGY, 2010
BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2010
Performance of Prediction Models for BRCA Mutation Carriage in Three Racial
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009
In reply to 'Tailoring BRCRAPRO to Asian Americans?' by S. Chen et al
JOURNAL OF CLINICAL ONCOLOGY, 2009
The Decline in Breast Cancer Incidence: Real or Imaginary?
CURRENT ONCOLOGY REPORTS, 2009
Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease.
Current breast cancer reports, 2009
Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers
FAMILIAL CANCER, 2008
Magnetic resonance galactography
BREAST JOURNAL, 2008
A carrier of both MEN1 and BRCA2 mutations: case report a-lid review of the literature
CANCER GENETICS AND CYTOGENETICS, 2007
CDH1 truncating mutations in the E-cadherin gene
ANNALS OF SURGERY, 2007
Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage
BREAST JOURNAL, 2007
Biomedical terahertz imaging with a quantum cascade laser
APPLIED PHYSICS LETTERS, 2006
Opinions of women with high inherited breast cancer risk about prophylactic mastectomy
HEALTH EXPECTATIONS, 2005
Ductal lavage of fluid-yielding and non
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005
Breast magnetic resonance image screening
CANCER, 2004
What is Dr. Kurian's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Kurian's National Provider Identifier (NPI) number is 1144385758.
What common questions do patients ask about Dr. Kurian?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Kurian
What is Dr. Allison Kurian's specialty?
Dr. Kurian is a Medical Oncologist near Stanford, CA. An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options. Contact Dr. Kurian to book an appointment today.
Is this Dr. Allison Kurian affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Kurian is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
Where can I learn more about Medical Oncologist?
Explore Medical Oncologist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Allison Kurian accepting new patients in Stanford, CA?
Yes, Dr. Allison Kurian is accepting new patients at this time.
Does Dr. Allison Kurian offer online booking?
Please contact Dr. Kurian's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Allison Kurian?
Please contact Dr. Kurian's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Allison Kurian have?
Dr. Allison Kurian is certified by the American Board of Internal Medicine.
Other Medical Oncologist Near Stanford, CA
Hematologist
Accepting patientsMedical Oncologist
Accepting patientsMedical Oncologist
Accepting patients